Every Form 4 that Cel-Sci Corporation (CVM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CVM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CVM filings page.
CEL SCI CORP (CVM) reported that Chief Executive Officer and director Geert R. Kersten purchased 100,000 shares of restricted common stock directly from the company on August 25, 2026. The shares were bought at $1.38 per share, equal to the August 24, 2026 closing price, according to a footnote.
Following this purchase, Kersten’s reported direct holdings increased to 316,142 shares of common stock. He also reports 311,547 shares of common stock held indirectly as Trustee, shown as a separate holding entry.
CEL SCI CORP director Robert Eugene Watson reported a grant of 110,000 stock options on 2026-08-14. The options have an exercise price of $1.49 per share, an associated grant value of $0.01 per option, and expire on 2036-08-13. They vest in three equal annual installments starting one year after the grant date and are exercisable for 110,000 shares of common stock. Following this award, Watson holds 137,271 options directly.
CEL-SCI Corp (CVM) director Bruno Jean-Marie Baillavoine reported a grant of 110,000 stock options on 2026-08-14. The options have an exercise price of $1.49 per share, a nominal grant-date value of $0.01 per option, and expire on 2036-08-13. They vest in three equal annual installments commencing one year after the grant date. Following this grant, Baillavoine holds 138,021 options in total, all reported as directly owned.
CEL-SCI Corp reported that Senior Vice President John Cipriano received a grant of 80,000 stock options on 2026-08-14. The options have an exercise price of $1.49 per share, a stated value of $0.01 per option, and expire on 2036-08-13. Following this grant, Cipriano holds 118,010 options directly. According to the grant terms, the options vest in three equal annual installments starting one year after the grant date.
CEL-SCI Corp (CVM) reported that Chief Scientific Officer Talor Eyal received a grant of 250,000 options to acquire Common Stock. The options have an exercise price of $1.49 per share, expire on August 13, 2036, and vest in three equal annual installments starting one year after the grant date. Following this award, Eyal directly holds 331,625 options in total.
CEL SCI CORP Chief Financial Officer Patricia B. Prichep received a grant of stock options covering 225,000 shares of common stock. The options have an exercise price of $1.49 per share, a reported transaction price of $0.01 per option, and expire on August 13, 2036. They vest in three equal annual installments beginning one year after the grant date. Following this award, she holds 299,693 options in total.
CEL SCI CORP director and Chief Executive Officer Geert R. Kersten received a grant of 300,000 stock options on 2026-08-14. The options have an exercise price of $1.49 per share, a grant-date fair value of $0.01 per option, and expire on 2036-08-13. They vest in three equal annual installments starting one year after the grant date. Following this grant, Kersten directly holds 452,380 options in total.
TALOR EYAL reported acquisition or exercise transactions in this Form 4 filing.
CEL SCI CORP Chief Scientific Officer receives stock grant. Chief Scientific Officer Talor Eyal was granted 2,307 shares of CEL SCI CORP common stock at a reference price of $1.04 per share. After this compensation-related award, Eyal directly holds a total of 9,318 common shares.
CEL SCI CORP Chief Financial Officer Patricia B. Prichep received a grant or award of 4,125 shares of common stock on June 30, 2026 at a reported value of $1.04 per share. After this acquisition, she directly owns 17,489 shares of the company’s common stock.
CEL-SCI Corp Chief Executive Officer Geert R. Kersten reported a compensation-related acquisition of 5,192 shares of common stock at $1.04 per share. Following this grant, he directly holds 216,142 common shares and indirectly holds 311,547 common shares as trustee.
CEL SCI CORP director and CEO Geert Kersten reported a significant insider purchase through a related trust. On May 14, 2026, the de Clara Trust, for which Mr. Kersten serves as trustee, bought 300,000 shares of restricted common stock directly from the company at $1.20 per share, equal to the most recent closing price on May 13, 2026.
After this transaction, Mr. Kersten is shown with 210,950 common shares held directly and 311,547 common shares held indirectly as trustee of the de Clara Trust. The filing shows no derivative securities remaining after this activity.
CEL SCI CORP director and Chief Executive Officer Geert R. Kersten reported buying additional company shares. On May 13, 2026, he purchased 100,000 shares of restricted common stock directly from the company at $1.19 per share, equal to the May 12, 2026 closing price. Following this transaction, his direct holdings increased to 222,497 common shares, indicating a substantial expansion of his personal equity stake.
CEL SCI CORP Chief Scientific Officer Talor Eyal reported an acquisition of 747 shares of Common Stock on 2026-03-31. The shares were characterized as a grant, award, or other acquisition at a reported value of $3.21 per share. Following this transaction, Eyal directly holds 7,011 shares of CEL SCI CORP common stock.
PRICHEP PATRICIA B reported acquisition or exercise transactions in this Form 4 filing.
CEL-SCI Corp Chief Financial Officer Patricia B. Prichep received a grant of 1,336 shares of Common Stock on March 31, 2026. The grant is recorded at $3.21 per share and brings her direct holdings to 13,364 shares, reflecting a routine compensation-related equity award.
KERSTEN GEERT R reported acquisition or exercise transactions in this Form 4 filing.
CEL SCI CORP reported that Chief Executive Officer Geert R. Kersten received a stock grant of 1,682 shares of common stock on March 31, 2026. The grant was valued at $3.21 per share. Following this award, he directly holds 122,497 common shares.
CEL-SCI Corp's Chief Executive Officer and director Geert Kersten purchased 38,023 shares of the company’s common stock on January 22, 2026 at $5.26 per share.
According to the filing, these were shares of restricted stock bought directly from the company at the closing price on January 21, 2026, which was the most recent closing price available. After this transaction, Kersten directly owns 120,815 shares of CEL-SCI common stock.
CEL-SCI Corporation's Chief Scientific Officer, Eyal Talor, reported a small open-market purchase of company stock. On 12/31/2025, he acquired 456 shares of common stock at a price of $5.26 per share. Following this transaction, he beneficially owns 6,264 shares of CEL-SCI common stock in direct ownership. This filing reflects personal share accumulation by a senior officer rather than a company-level financing or business event.
CEL-SCI Corporation's Chief Financial Officer, Patricia Prichep, reported acquiring additional common stock in the company. On 12/31/2025, she acquired 815 shares of CEL-SCI common stock at a price of $5.26 per share. Following this transaction, she beneficially owned 12,028 shares of CEL-SCI common stock in direct ownership. This insider transaction reflects a modest increase in the CFO’s personal stake in the company.
CEL-SCI Corp insider activity: Chief Executive Officer and Director Geert Kersten reported acquiring 998 shares of CEL-SCI common stock on 12/31/2025 at a price of $5.26 per share. Following this transaction, he beneficially owns 82,792 shares held directly.
CEL-SCI Corp (CVM) reported an insider stock purchase by its Chief Executive Officer and director, Geert Kersten. On December 4, 2025, Kersten bought 8,389 shares of CEL-SCI common stock in an open market-style transaction coded as a purchase. The filing reports a purchase price of $5.96 per share, matching the company’s closing price on December 3, 2025, which the company used as the most recent closing price available.
Following this transaction, Kersten beneficially owns 81,794 shares of CEL-SCI common stock directly. The filing is made on Form 4, which discloses changes in ownership by company insiders such as directors and executive officers.
Form 4 filed for CEL-SCI Corp (CVM) discloses that the reporting person, identified as an officer with the title Chief Scientific Officer, executed a purchase on 09/30/2025. The report shows an acquisition of 260 shares of Common Stock at a price of $9.20 per share, resulting in 5,808 shares beneficially owned following the transaction. The Form is signed by the reporting person on 10/02/2025.
Patricia Prichep, Chief Financial Officer of CEL-SCI Corporation (CVM), reported an open-market purchase of company common stock. On 09/30/2025 she acquired 466 shares at a reported price of $9.20 per share. After this transaction she beneficially owns 11,213 shares directly. The filing is a Form 4 statement of changes in beneficial ownership and is signed by Ms. Prichep on 10/02/2025. The report identifies her relationship to the issuer as an officer with the title Chief Financial Officer.
Geert Kersten, listed as Chief Executive Officer and a director of CEL-SCI Corporation (CVM), reported an open-market purchase of 570 shares of CEL-SCI common stock on 09/30/2025 at a price of $9.20 per share. After this transaction the filing shows 73,405 shares beneficially owned directly. The Form 4 was signed on 10/02/2025. The report contains no derivative transactions and includes no additional explanatory disclosures.